JP4965745B2 - 含窒素脂環式骨格を有する一本鎖核酸分子 - Google Patents

含窒素脂環式骨格を有する一本鎖核酸分子 Download PDF

Info

Publication number
JP4965745B2
JP4965745B2 JP2011537085A JP2011537085A JP4965745B2 JP 4965745 B2 JP4965745 B2 JP 4965745B2 JP 2011537085 A JP2011537085 A JP 2011537085A JP 2011537085 A JP2011537085 A JP 2011537085A JP 4965745 B2 JP4965745 B2 JP 4965745B2
Authority
JP
Japan
Prior art keywords
region
bases
nucleic acid
acid molecule
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011537085A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2012017919A1 (ja
Inventor
忠明 大木
宏剛 林
久男 白水
智洋 濱崎
彰浩 伊藤
鈴木　　寛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bonac Corp
Original Assignee
Bonac Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bonac Corp filed Critical Bonac Corp
Priority to JP2011537085A priority Critical patent/JP4965745B2/ja
Application granted granted Critical
Publication of JP4965745B2 publication Critical patent/JP4965745B2/ja
Publication of JPWO2012017919A1 publication Critical patent/JPWO2012017919A1/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/30—Production chemically synthesised

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2011537085A 2010-08-03 2011-07-28 含窒素脂環式骨格を有する一本鎖核酸分子 Expired - Fee Related JP4965745B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011537085A JP4965745B2 (ja) 2010-08-03 2011-07-28 含窒素脂環式骨格を有する一本鎖核酸分子

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
JP2010174915 2010-08-03
JP2010174915 2010-08-03
JP2010230806 2010-10-13
JP2010230806 2010-10-13
JP2010269823 2010-12-02
JP2010269823 2010-12-02
JP2011152381 2011-07-08
JP2011152381 2011-07-08
PCT/JP2011/067292 WO2012017919A1 (ja) 2010-08-03 2011-07-28 含窒素脂環式骨格を有する一本鎖核酸分子
JP2011537085A JP4965745B2 (ja) 2010-08-03 2011-07-28 含窒素脂環式骨格を有する一本鎖核酸分子

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012026878A Division JP5261677B2 (ja) 2010-08-03 2012-02-10 含窒素脂環式骨格を有する一本鎖核酸分子

Publications (2)

Publication Number Publication Date
JP4965745B2 true JP4965745B2 (ja) 2012-07-04
JPWO2012017919A1 JPWO2012017919A1 (ja) 2013-10-03

Family

ID=45559420

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2011537085A Expired - Fee Related JP4965745B2 (ja) 2010-08-03 2011-07-28 含窒素脂環式骨格を有する一本鎖核酸分子
JP2012026878A Expired - Fee Related JP5261677B2 (ja) 2010-08-03 2012-02-10 含窒素脂環式骨格を有する一本鎖核酸分子
JP2013048777A Expired - Fee Related JP5555346B2 (ja) 2010-08-03 2013-03-12 含窒素脂環式骨格を有する一本鎖核酸分子

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012026878A Expired - Fee Related JP5261677B2 (ja) 2010-08-03 2012-02-10 含窒素脂環式骨格を有する一本鎖核酸分子
JP2013048777A Expired - Fee Related JP5555346B2 (ja) 2010-08-03 2013-03-12 含窒素脂環式骨格を有する一本鎖核酸分子

Country Status (10)

Country Link
US (3) US8691782B2 (enExample)
EP (4) EP2436767B1 (enExample)
JP (3) JP4965745B2 (enExample)
KR (3) KR101849801B1 (enExample)
CN (3) CN104059911B (enExample)
DK (1) DK2674494T3 (enExample)
ES (4) ES2533129T3 (enExample)
PT (1) PT2674494E (enExample)
TW (2) TWI572716B (enExample)
WO (1) WO2012017919A1 (enExample)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018182008A1 (ja) 2017-03-31 2018-10-04 株式会社ボナック 遺伝子発現制御機能を有する環状型核酸分子
WO2021070494A1 (ja) 2019-10-11 2021-04-15 住友化学株式会社 核酸オリゴマーの製造方法
WO2021153770A1 (en) 2020-01-29 2021-08-05 Sumitomo Chemical Company, Limited Process of preparing nucleic acid oligomer
WO2021153047A1 (ja) 2020-01-29 2021-08-05 住友化学株式会社 核酸オリゴマーの製造方法
WO2021193954A1 (ja) 2020-03-27 2021-09-30 住友化学株式会社 核酸オリゴマーの製造方法
WO2022009959A1 (ja) 2020-07-09 2022-01-13 住友化学株式会社 核酸オリゴマーの製造方法
WO2022064908A1 (ja) 2020-09-24 2022-03-31 住友化学株式会社 核酸オリゴマーの製造方法
WO2023054350A1 (ja) 2021-09-28 2023-04-06 住友化学株式会社 精製ジクロロ酢酸の製造方法
WO2023182274A1 (ja) 2022-03-23 2023-09-28 住友化学株式会社 核酸オリゴマーの製造方法

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2533129T3 (es) 2010-08-03 2015-04-07 Bonac Corporation Molécula de ARN monocatenario que tiene esqueleto alicíclico que contiene nitrógeno
WO2013077446A1 (ja) * 2011-11-26 2013-05-30 株式会社ボナック 遺伝子発現制御のための一本鎖核酸分子
EP3254700B1 (en) 2012-03-04 2019-10-23 Bonac Corporation Micro-rna inhibitor
WO2013133393A1 (ja) * 2012-03-07 2013-09-12 学校法人東京医科大学 Ｖｅｇｆ遺伝子の発現抑制用一本鎖核酸分子
JP6283859B2 (ja) * 2012-03-29 2018-02-28 国立大学法人九州大学 ペリオスチン遺伝子の発現抑制核酸分子、ペリオスチン遺伝子の発現抑制方法、およびその用途
US9663784B2 (en) 2012-05-26 2017-05-30 Bonac Corporation Single-stranded nucleic acid molecule for regulating expression of gene having delivering function
WO2015046451A1 (ja) * 2013-09-27 2015-04-02 株式会社アクアセラピューティクス 眼科疾患を除くペリオスチン発現に起因する疾患用医薬、およびその用途
WO2015093495A1 (ja) * 2013-12-16 2015-06-25 株式会社ボナック ＴＧＦ－β１遺伝子発現制御のための一本鎖核酸分子
WO2015099122A1 (ja) 2013-12-26 2015-07-02 学校法人東京医科大学 遺伝子発現制御のための人工ミミックｍｉＲＮＡおよびその用途
SG10201805087VA (en) * 2013-12-27 2018-07-30 Bonac Corp Artificial match-type mirna for controlling gene expression and use therefor
WO2015099188A1 (ja) * 2013-12-27 2015-07-02 株式会社ボナック 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途
HK1244035A1 (en) * 2014-12-15 2018-07-27 Bonac Corporation Single-stranded nucleic acid molecule for inhibiting tgf- beta 1 expression
WO2016104775A1 (ja) 2014-12-27 2016-06-30 株式会社ボナック 遺伝子発現制御のための天然型ｍｉＲＮＡおよびその用途
HK1244030A1 (en) * 2014-12-29 2018-07-27 东丽株式会社 Composition containing nucleic acid molecule stably
JP6602847B2 (ja) 2015-03-27 2019-11-06 株式会社ボナック デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子
JPWO2016167366A1 (ja) * 2015-04-17 2018-04-05 国立大学法人 東京大学 眼疾患治療剤
EP3369816B1 (en) 2015-10-30 2024-03-13 Toray Industries, Inc. Composition stably containing single-stranded nucleic acid molecule that suppresses expression of tgf-beta1 gene
JP6634095B2 (ja) * 2015-12-29 2020-01-22 国立大学法人北海道大学 プロレニン遺伝子またはプロレニン受容体遺伝子の発現を抑制する一本鎖核酸分子およびその用途
EP3409779A4 (en) * 2016-01-26 2019-07-03 Nissan Chemical Corporation Single-stranded oligonucleotide
WO2017131237A1 (ja) * 2016-01-30 2017-08-03 株式会社ボナック 人工単一ガイドｒｎａ及びその用途
ES2853732T3 (es) * 2016-04-26 2021-09-17 Sumitomo Chemical Co Método de producción de un monómero para una molécula de ácido nucleico monocatenario
JP7188087B2 (ja) * 2017-02-06 2022-12-13 日産化学株式会社 一本鎖オリゴヌクレオチド
WO2018199338A1 (ja) * 2017-04-27 2018-11-01 国立大学法人広島大学 Ｂ型肝炎治療用核酸分子
WO2019022257A1 (ja) * 2017-07-28 2019-01-31 杏林製薬株式会社 線維症治療剤
WO2019074110A1 (ja) 2017-10-13 2019-04-18 株式会社ボナック 一本鎖核酸分子およびその製造方法
TWI830718B (zh) * 2018-02-09 2024-02-01 日商住友化學股份有限公司 核酸分子之製造方法
EP3770256A4 (en) 2018-03-20 2021-12-22 Tokyo Institute of Technology ANTISENSE OLIGONUCLEOTIDE WITH REDUCED TOXICITY
US20210115485A1 (en) * 2018-03-30 2021-04-22 Sumitomo Chemical Company, Limited Method for producing single-strand rna
EP3778886A4 (en) 2018-03-30 2022-11-02 Toray Industries, Inc. Method for producing hairpin single-stranded rna molecule
US11401296B2 (en) 2018-04-24 2022-08-02 Sumitomo Chemical Company, Limited Amidite compound and method for producing polynucleotide using said compound
CN112673102A (zh) * 2018-10-02 2021-04-16 东丽株式会社 发夹型单链rna分子的制备方法
WO2020152869A1 (ja) 2019-01-25 2020-07-30 杏林製薬株式会社 線維症治療剤
WO2020202952A1 (ja) 2019-03-29 2020-10-08 住友化学株式会社 無機多孔質担体、及びこれを用いた核酸の製造方法
JP7368456B2 (ja) 2019-03-29 2023-10-24 住友化学株式会社 無機多孔質担体、及びこれを用いた核酸の製造方法
US12371451B2 (en) 2019-03-29 2025-07-29 Sumitomo Chemical Company, Limited Inorganic porous carrier and method for producing nucleic acids using same
US12378275B2 (en) 2019-03-29 2025-08-05 Sumitomo Chemical Company, Limited Porous inorganic carrier and method for producing nucleic acid using same
EP3950695A4 (en) 2019-03-29 2023-01-25 Sumitomo Chemical Company, Limited PROCEDURE FOR PRODUCTION OF RNA
EP4151597B1 (en) 2020-05-13 2026-04-15 Sumitomo Chemical Company, Limited Inorganic porous substrate, inorganic porous support, and nucleic acid production method

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004015075A2 (en) * 2002-08-08 2004-02-19 Dharmacon, Inc. Short interfering rnas having a hairpin structure containing a non-nucleotide loop
WO2004090108A2 (en) * 2003-04-03 2004-10-21 Alnylam Pharmaceuticals Irna conjugates
WO2005019453A2 (en) * 2001-05-18 2005-03-03 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
WO2008116094A2 (en) * 2007-03-21 2008-09-25 Brookhaven Science Associates, Llc Combined hairpin-antisense compositions and methods for modulating expression
WO2009073809A2 (en) * 2007-12-04 2009-06-11 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5631148A (en) 1994-04-22 1997-05-20 Chiron Corporation Ribozymes with product ejection by strand displacement
GB9621367D0 (en) * 1996-10-14 1996-12-04 Isis Innovation Chiral peptide nucleic acids
US6509323B1 (en) 1998-07-01 2003-01-21 California Institute Of Technology Linear cyclodextrin copolymers
FR2790757B1 (fr) 1999-03-09 2003-08-01 Bioalliance Pharma Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
US6962906B2 (en) * 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
TWI321054B (en) 2000-12-19 2010-03-01 California Inst Of Techn Compositions containing inclusion complexes
WO2003072745A2 (en) * 2002-02-22 2003-09-04 Eshleman James R Antigene locks and therapeutic uses thereof
WO2003079757A2 (en) 2002-03-20 2003-10-02 Massachusetts Institute Of Technology Hiv therapeutic
EP1857547B2 (en) 2002-08-05 2020-12-02 Silence Therapeutics GmbH Further novel forms of interfering RNA molecules
US6936651B2 (en) 2002-12-17 2005-08-30 E. I. Du Pont De Nemours And Company Compatibility improvement in crystalline thermoplastics with mineral fillers
NL1022811C2 (nl) * 2003-02-28 2004-08-31 Fountain Patents B V Systeem en werkwijze voor opslag en transport van zeecontainers.
US7595301B2 (en) 2003-09-30 2009-09-29 Anges Mg, Inc. Staple type oligonucleotide and drug comprising the same
JP2008504840A (ja) * 2004-06-30 2008-02-21 アルニラム ファーマスーティカルズ インコーポレイテッド 非リン酸骨格結合を含むオリゴヌクレオチド
JP2008526213A (ja) 2004-12-30 2008-07-24 トッド エム． ハウザー， 自己保護オリゴヌクレオチドを使用する、遺伝子発現を調節するための組成物および方法
US8846697B2 (en) * 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 １本鎖環状ｒｎａおよびその製造方法
EP2171089B1 (en) * 2007-06-25 2014-01-22 Universität Duisburg-Essen Screening-method for polymorphic markers in htra1 gene in neurodegenerative disorders
US20100317714A1 (en) * 2007-11-29 2010-12-16 Suzhou Ribo Life Science Co., Ltd Complex molecule interfering the expression of target genes and its preparing methods
US20110159586A1 (en) * 2007-12-07 2011-06-30 Halo-Bio Rnai Therapeutics, Inc. Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides
EP2256191A4 (en) 2008-02-15 2011-07-06 Riken CYCLIC SINGLE NUCLEIC ACID COMPLEX AND METHOD FOR THE PRODUCTION THEREOF
JP2010174915A (ja) 2009-01-27 2010-08-12 Toyota Motor Corp 高圧ガスタンク
JP5449815B2 (ja) 2009-03-26 2014-03-19 住友化学株式会社 偏光板の製造方法
JP2010269823A (ja) 2009-05-21 2010-12-02 British American Tobacco Japan Kk 喫煙品用容器
US20110052666A1 (en) 2009-09-03 2011-03-03 Medtronic, Inc. Compositions, Methods, and Systems for SIRNA Delivery
JP2011152381A (ja) 2010-01-25 2011-08-11 Ucom:Kk 箸置き
JP5555940B2 (ja) 2010-04-14 2014-07-23 国立大学法人佐賀大学 増殖糖尿病網膜症の検出方法および予防・治療剤のスクリーニング方法
WO2011132672A1 (ja) 2010-04-19 2011-10-27 独立行政法人理化学研究所 機能性核酸の安定化法
SG186899A1 (en) 2010-07-08 2013-02-28 Bonac Corp Single-strand nucleic acid molecule for controlling gene expression
ES2533129T3 (es) 2010-08-03 2015-04-07 Bonac Corporation Molécula de ARN monocatenario que tiene esqueleto alicíclico que contiene nitrógeno

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019453A2 (en) * 2001-05-18 2005-03-03 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA)
WO2004015075A2 (en) * 2002-08-08 2004-02-19 Dharmacon, Inc. Short interfering rnas having a hairpin structure containing a non-nucleotide loop
WO2004090108A2 (en) * 2003-04-03 2004-10-21 Alnylam Pharmaceuticals Irna conjugates
WO2008116094A2 (en) * 2007-03-21 2008-09-25 Brookhaven Science Associates, Llc Combined hairpin-antisense compositions and methods for modulating expression
WO2009073809A2 (en) * 2007-12-04 2009-06-11 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018182008A1 (ja) 2017-03-31 2018-10-04 株式会社ボナック 遺伝子発現制御機能を有する環状型核酸分子
WO2021070494A1 (ja) 2019-10-11 2021-04-15 住友化学株式会社 核酸オリゴマーの製造方法
WO2021153770A1 (en) 2020-01-29 2021-08-05 Sumitomo Chemical Company, Limited Process of preparing nucleic acid oligomer
WO2021153047A1 (ja) 2020-01-29 2021-08-05 住友化学株式会社 核酸オリゴマーの製造方法
WO2021193954A1 (ja) 2020-03-27 2021-09-30 住友化学株式会社 核酸オリゴマーの製造方法
WO2022009959A1 (ja) 2020-07-09 2022-01-13 住友化学株式会社 核酸オリゴマーの製造方法
WO2022064908A1 (ja) 2020-09-24 2022-03-31 住友化学株式会社 核酸オリゴマーの製造方法
WO2023054350A1 (ja) 2021-09-28 2023-04-06 住友化学株式会社 精製ジクロロ酢酸の製造方法
WO2023182274A1 (ja) 2022-03-23 2023-09-28 住友化学株式会社 核酸オリゴマーの製造方法

Also Published As

Publication number Publication date
ES2443346T3 (es) 2014-02-19
JPWO2012017919A1 (ja) 2013-10-03
WO2012017919A1 (ja) 2012-02-09
EP2674494B1 (en) 2014-12-17
ES2527660T3 (es) 2015-01-28
US8691782B2 (en) 2014-04-08
EP2674494A1 (en) 2013-12-18
EP2628801A1 (en) 2013-08-21
TWI572716B (zh) 2017-03-01
JP2013138681A (ja) 2013-07-18
CN103052711A (zh) 2013-04-17
EP2639307A2 (en) 2013-09-18
EP2436767A4 (en) 2012-05-09
CN104059911A (zh) 2014-09-24
US20140171633A1 (en) 2014-06-19
US9206422B2 (en) 2015-12-08
TW201219570A (en) 2012-05-16
JP5555346B2 (ja) 2014-07-23
US20120035246A1 (en) 2012-02-09
PT2674494E (pt) 2015-02-27
KR101849801B1 (ko) 2018-04-17
EP2639307A3 (en) 2014-02-05
DK2674494T3 (en) 2015-02-23
EP2639307B1 (en) 2015-03-04
HK1200460A1 (zh) 2015-08-07
ES2533129T3 (es) 2015-04-07
TW201615835A (zh) 2016-05-01
JP2013034470A (ja) 2013-02-21
KR20180040727A (ko) 2018-04-20
KR101894701B1 (ko) 2018-09-04
CN103052711B (zh) 2016-08-03
EP2628801B1 (en) 2015-01-07
US20140171486A1 (en) 2014-06-19
EP2436767A1 (en) 2012-04-04
CN104004018B (zh) 2017-01-04
ES2528285T3 (es) 2015-02-06
KR101894702B1 (ko) 2018-09-04
EP2639307A8 (en) 2014-04-30
TWI515294B (zh) 2016-01-01
KR20130095738A (ko) 2013-08-28
CN104004018A (zh) 2014-08-27
CN104059911B (zh) 2017-01-04
KR20180040728A (ko) 2018-04-20
HK1189910A1 (en) 2014-06-20
JP5261677B2 (ja) 2013-08-14
US9200278B2 (en) 2015-12-01
EP2436767B1 (en) 2013-11-20

Similar Documents

Publication Publication Date Title
JP5555346B2 (ja) 含窒素脂環式骨格を有する一本鎖核酸分子
JP6162182B2 (ja) 遺伝子発現制御のための一本鎖核酸分子
JP5876890B2 (ja) アミノ酸骨格を有する一本鎖核酸分子
WO2013077446A1 (ja) 遺伝子発現制御のための一本鎖核酸分子
JP2013153736A (ja) ペプチド骨格を有する一本鎖核酸分子
JP2013055913A (ja) 遺伝子発現制御のための一本鎖ｒｎａ分子
HK1200460B (en) Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
HK1181423B (en) Single-strand nucleic acid molecule for controlling gene expression

Legal Events

Date Code Title Description
TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120321

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120329

R150 Certificate of patent or registration of utility model

Ref document number: 4965745

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150406

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees